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Rhabdoid meningioma is an uncommon meningioma
variant categorized as WHO grade III. The majority of
cases occur in adulthood. Herein, we describe a right
fronto-temporal rhabdoid meningioma affecting a 3-year-
old boy. The lesion measured approximately 4 cm in diam-
eter and incorporated the ipsilateral middle cerebral
artery. Sub-total surgical excision of the mass was per-
formed. Histologically, the tumor was mainly composed of
globoid plump cells with inclusion-like eosinophilic cyto-
plasm, peripheral nuclei, prominent nucleoli and occa-
sional intra-nuclear cytoplasmic pseudo-inclusion. The
cells appeared in many areas loosely arranged and focally
disclosed a papillary architecture. At immunohistochemis-
try, the tumor cells were EMA, vimentin, HHF35, PgR,
INI-1 and p53 positive. The proliferative index (Mib-1) was
15% in the most positive areas. Ultrastructurally, tumoral
cells showed an abundant cytoplasm, which was filled with
numerous intermediate filaments. Desmosomal junctions
were seen. RT-PCR revealed the presence of NF2 gene
expression. Molecular study did not indicate alterations
of the INI-1 gene, whereas it showed the presence of
Pro72Arg in exon 4 at heterozygous state in the TP53
gene. Morphologic features along with immunohistochemi-
cal, ultrastructural and molecular results were consistent
with the diagnosis of rhabdoid meningioma. The patient
was treated with chemotherapy. The lesion remained stable
after 33 months of follow-up. Rhabdoid meningiomas
rarely occur in children. Owing to its rarity, each new case
should be recorded to produce a better clinical, pathologi-
cal, molecular, prognostic and therapeutic characterization
of this lesion.
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INTRODUCTION
Brain tumors are the most common solid malignancies in
childhood. A wide spectrum of primary brain tumors that
differ in etiology, morphology, response to radiotherapy or
chemotherapy and prognosis, may arise in the pediatric age
group. However, childhood meningiomas are infrequent.
The majority of them occur in the setting of particular risk
factors, including neurofibromatosis type 2 syndrome and
prior radiation.1
Herein, we describe a rare case of rhabdoid meningioma
affecting a 3-year-old boy. The morphological, immunohis-
tochemical, ultrastructural and molecular (TP53, NF2,
INI-1) traits of this tumor are described.
CLINICAL HISTORY
A 3-year-old boy, with a recent history of seizures, was
admitted to the Neurosurgery Unit of the Meyer Chil-
dren’s Hospital. He was the full-term result of a normal
pregnancy. Family history was unremarkable. Neurocuta-
neous stigmata were absent. His weight was 17 kg and his
cranial circumference was 50 cm.There were no neurologi-
cal focal deficits or signs and symptoms of cranial hyper-
tension. CT scan and MRI showed a right fronto-temporal
inhomogeneous, hypervascularized and calcified mass mea-
suring approximately 4 cm in diameter. It involved the
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orbital fissure and the lesser sphenoidal wing and entirely
occupied the temporal fossa incorporating the ipsilateral
middle cerebral artery. The lesion determined mass effect
with consequent midline shift and was accompanied by
basal hyperostosis (Fig. 1a). A right pterional craniotomy
was performed. During surgery the mass, which arose from
the meninges, appeared not well demarcated from the per-
ilesional parenchyma, particularly in the sylvian area. Post-
surgical radiological studies showed a sub-total excision
(Fig. 1b). Due to the absence of any consolidated therapy
for pediatric rhabdoid meningioma and in consideration of
the young age, the patient was treated with chemotherapy
(ICE: ifosfamide, carboplatin and etoposide). The therapy
was tolerated well. At revaluations the child achieved
radiological and clinical stabilization for a period of 33
months.
METHODS
Optic microscopy and immunohistochemistry
The surgical specimen was fixed in 10% buffered neutral
formalin and embedded in paraffin. Some 5 mm sections
were stained with HE for the morphological evaluation,
whereas further 5 mm sections of the most representative
specimen were mounted on electrostatic slides and used
for the immunohistochemical studies. Immunohisto-
chemical studies were performed using the standard
streptavidin-biotin technique and commercially available
reagents (epithelial membrane antigen, EMA, clone E29:
DAKO CYTOMATION, Glostrup, Denmark; vimentin,
VIM, clone V9: Bio-Genex, San Ramon, CA, USA; GFAP,
clone ZCG29: Zymed Laboratory, San Francisco, CA,
USA; S-100 protein, polyclonal: DAKO CYTOMATION;
smooth muscle actin, clone 1A4: Cell Marque Corporation,
Rocklin, CA, USA; muscle-specific actin, clone HHF35:
Cell Marque; synaptophysin, SP, polyclonal: Cell Marque;
neurofilaments, NF, clone 2F11: Cell Marque; desmin, clone
DE-R-11: Ventana Medical Systems, Tucson, AZ, USA;
cytokeratins, clone AE1: Ventana; clone AE3: Ventana;
clone CAM 5.2: BD Biosciences, Becton Dickinson, San
Jose, CA, USA; estrogen and progesterone receptors, ER,
clone D15: Bio-Genex; PgR, clone 1A6: Bio-Genex; p53,
clone DO-7: Ventana; BAF47, INI-1, clone 25/BAF47: BD
Biosciences, Chicago, IL, USA; and Ki-67, clone Mib-1:
DAKO CYTOMATION.
Electron microscopy
Tissue for electron microscopy was obtained from the par-
affin block, post-fixed in osmium tetroxide, dehydrated in
graded ethanol, embedded in epoxy resin, and cut with a
diamond knife in a Leica Ultracut R microtome (Leica
Microsystems, Wien, Austria). Ultrathin sections were
stained with uranyl acetate and lead citrate, and viewed
with a Philips 410 LS transmission electron microscope
(Philips’ Gloeilampenfabrieken, Eindhoven, Netherlands).
RT-PCR and gene sequencing
From the fresh surgical specimen we selected a fragment
macroscopically representative of the tumor. Successively,
we cut it in half: from one half several 5-mm frozen sections
stained with HE were obtained to verify the adequacy of
the specimen (presence of pathological tissue only); the
other half was immersed in RNAlater™ (QIAGEN,Valen-
cia, CA, USA) and was kept overnight at +4°C and finally
stored at -80°C until analysis.
RNA isolation and real time-PCR
RNA was isolated from 5 mg tissue using 6100 Nucleic
Acid PrepStation (Applied Biosystems, Foster City, CA,
USA). RNA fragmentation state was evaluated by 1.5%
agarose gel. All RNA (200 ng) was reverse-transcribed to
cDNA using iScript cDNA Synthesis Kit (Biorad, Her-
cules, CA, USA). TaqMan real-time quantitative PCR was
Fig. 1 Preoperative MRI (gadolinium –
Gd-TPA – contrast medium) coronal section:
middle cranial fossa mass in conjunction with
the dura mater extending into the sylvian
fissure (a). Postoperative MRI (gadolinium –
Gd-TPA – contrast medium) coronal section:
residual tumor in the sylvian fissure with con-
tiguous middle cerebral artery (b).
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performed on an ABI PRISM 7000 Sequence Detector
System (Applied Biosystems). PCR product for NF2 and
GAPDH genes was detected using gene-specific primers
and probes (Applied Biosystems).
Mutation analysis
Genomic DNA from blood and tumor tissue were
extracted with QIAamp DNA Kit (QIAGEN, Milan, Italy)
according to the manufacture’s protocol and DNA con-
centrations were determined using spectrophotometer
GeneQuant II (Pharmacia, Cambridge, UK).
PCR amplifications of the complete coding sequence
and flanking exon-intron borders of the INI-1 (exons 1–9)
and TP53 (exons 2–11) were performed under standard
conditions using HotStarTaq DNA Polymerase (QIAGEN,
Milan, Italy). The sequencing reactions were performed by
means of BigDye Terminator v1.1 Cycle Sequencing Kit
(Applied Biosystems). Products of the sequencing reaction
were run and analyzed with the ABI Prism ® 3130 Genetic
Analyzer (Applied Biosystems).
Microsatellite analysis
We analyzed seven polymorphic microsatellite repeat
markers (D22S257, D22S427, D22S311, D22S1154,
D22S1174, D22S277, D22S1170) labeled with NED
(http://www3.appliedbiosystems.com) to evaluate loss of
heterozygosity (LOH) on chromosome 22 (22q). Amplifi-
cation was performed with 50 ng of genomic DNA from
normal and tumor tissue. Products were run on an ABI
PRISM 310 Genetic Analyzer (Applied Biosystems) and
analyzed with GeneScan and Genotyper softwares
(Applied Biosystems).
RESULTS
The lesion was mainly (more than 50%) composed of a
proliferation of globoid plump cells with inclusion-like
eosinophilic cytoplasm, peripheral nuclei, prominent
nucleoli and occasional intra-nuclear cytoplasmic pseudo-
inclusions. The cells appeared in many areas rather loosely
arranged and sometimes disclosed a papillary architecture.
In some areas, the lesion was constituted of spindle-shaped
cells and the interstitial space contained collagen bundles.
Focally, an organoid architectural pattern was also
observed (isles of spindle-shaped or globoid plump cells
delimited by smaller cuboidal cells) (Fig. 2a–e).There were
no whorls or psammoma bodies. Mitotic index ranged from
0–5 per 10 high-power fields. Hemorrhages and vascular
hyperplasia were evident. Focal areas of necrosis were also
present.
By immunohistochemical staining, the tumor cells were
EMA, VIM and p53 positive and GFAP, SP, NF, NSE, 1A4,
desmin, AE1/AE3, CAM5.2 and ER negative. S-100,
HHF35 and PgR were focally positive. Furthermore, the
tumor cells exhibited diffuse INI-1 nuclear staining. The
proliferative index, determined by estimating the percent-
age of the Mib-1 positive neoplastic cells in the total
tumoral cells in the most positive areas, was 15% (Fig. 3a–
c).
Ultrastructurally, neoplastic cells showed a round to
oval shape with peripherally located nucleus and abundant
cytoplasm, which was filled with numerous intermediate
filaments and contained few organelles, including rough
endoplasmic reticulum profiles, Golgi cysternae, and a
small amount of mitochondria. Desmosomal junctions
between adjacent cells were seen (Fig. 4).
The RT-PCR revealed the presence of NF2 gene expres-
sion in the tissue sample.
Molecular analysis of INI-1 gene did not show any
variation in sequence or LOH at D22S257, D22S1154,
D22S1174, D22S277 and D22S1170 loci. D22S427 and
D22S311 were not informative.TP53 gene analysis showed
the presence of Pro72Arg in exon 4 at the heterozygous
state (Fig. 5).
Morphologic features along with immunohistochemical,
ultrastructural and molecular results were consistent with
the diagnosis of rhabdoid meningioma.
DISCUSSION
Meningiomas are frequent primary intracranial neoplasms
(approximately 25% of all primary tumors in this site)
arising from the leptomeningeal covering of the CNS.They
predominantly affect middle-aged and elderly women.
Radiation exposure, hormonal and genetic factors play a
role in their development and growth. Meningiomas are
usually sporadic but may also be a manifestation of the
hereditary syndrome neurofibromatosis type 2, which is
characterized, at the nervous system level, by the develop-
ment of schwannomas, meningiomas, ependymomas,
and occasionally, gliomas and neurofibromas. The World
Health Organization (WHO) recognizes three histological
meningioma grades (WHO I or benign, WHO II or atypi-
cal, and WHO III or anaplastic) with an increasing risk of
recurrence and unfavorable outcome. Recurrence rates of
7–20%, 29–40% and 50–70% are reported, respectively, for
benign WHO I, atypical WHO II, and anaplastic WHO III
meningiomas. Meningiomas exhibit a wide range of histo-
logical patterns with numerous classified subtypes and
several uncategorized subtypes. In most cases histological
variants do not have prognostic significance. However,
clear cell, chordoid, papillary and rhabdoid meningiomas
are clinically aggressive.2–4 Meningiomas are rare in the
pediatric population. Indeed, although tumors of the CNS
are the second most common neoplasms in children,
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Fig. 2 Globoid and loosely arranged tumoral cells showing an eosinophilic ample hyaline cytoplasm, peripheral nuclei, prominent
nucleoli (a) and occasional intra-nuclear cytoplasmic pseudo-inclusions (b); papillary architecture (c); spindle-shaped cells (d); organoid
architectural pattern (isle of globoid cells delimited by smaller cuboidal cells) (e). HE; original magnification: a, c–e ¥200; b ¥400.
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intracranial meningiomas account for only 1% to 4.2% of
all brain tumors in this age group.5,6
Rhabdoid meningioma is an uncommon meningioma
variant composed of plump cells with abundant eosino-
philic fibrillary to hyaline cytoplasm, eccentric nuclei and
prominent nucleoli. The majority of the cases have a high
proliferative index and other histological features of malig-
nancy. Some cases combine the features of the papillary and
rhabdoid types. Rhabdoid meningiomas often undergo an
aggressive clinical course and are categorized as WHO
grade III. Nevertheless, a minority of rhabdoid meningio-
mas show inconspicuous histological features of malig-
nancy. The behavior of these cases remains to be
determined.4 The majority of rhabdoid meningiomas occur
in adulthood. In fact, only 11 juvenile cases have been
reported in the international literature (the majority of
these patients, 6/11, 55%, were teenagers; only 2, 18%, were
preschool children). Adjuvant therapy is considered essen-
tial in the management of rhabdoid meningiomas. The
outcome of the few reported juvenile rhabdoid meningio-
mas seems to be better than their adult counterparts. In fact,
in the group of 11 juvenile reported rhabdoid meningiomas,
there was only one recurrence (4 months after the surgery)
and one death (25 years after the surgery).7–12 Nevertheless,
the small number of reported pediatric rhabdoid meningio-
mas makes conclusive prognostic remarks difficult.
In our patient the disease is stable 33 months after the
diagnosis. This datum could confirm the hypothesis that
rhabdoid meningioma has a relatively less aggressive
behavior in children.12 On the other hand, the present case
showed alterations in the p53 protein and TP53 gene (p53
over-expression and TP53 alteration – Pro72Arg variation
allele).The p53 has been shown to be an important protein,
associated with cell cycle control, cell differentiation, main-
tenance of genomic stability, senescence and apoptosis.




Fig. 3 p53 (a), INI-1 (b) and vimentin (VIM) (c) immunostaining; whorled intermediate filaments which are VIM-positive are visible (the
arrows indicate some of them) (c). Original magnification: a–c ¥200.
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ominous feature in many tumors. In respect to meningio-
mas, a number of studies suggest a correlation of p53
inactivation with histological tumor grade and risk of
recurrence.13,14 However, the prognostic significance of
Pro72Arg variation allele in meningiomas has not yet been
determined.
The observation in the pediatric age group of a CNS
tumor showing rhabdoid features mainly suggests the pos-
sible diagnosis of atypical teratoid/rhabdoid tumor. It
is a highly malignant embryonal tumor mostly affecting
infants. Atypical teratoid/rhabdoid tumor typically has
INI-1 gene mutations.4 INI-1 is a tumor suppressor gene
located on chromosome 22q11.2 and its product, the INI-1
protein, is involved in chromatin remodeling.15 In our case,
because of the young age of the patient, the possibility of
an atypical teratoid/rhabdoid tumor was taken into consid-
eration. Nevertheless, the immunohistochemical diffuse
INI-1 nuclear positivity of the neoplastic cells and the
absence of mutations of the INI-1 gene excluded this pos-
sibility (INI-1 mutations are not typical of rhabdoid men-
ingioma14). Moreover, the tumor was completely negative
to the glial and neuronal markers which are variably posi-
tive in atypical teratoid/rhabdoid tumor.4
With respect to the NF2 gene, it is an oncosuppressor
gene responsible for the hereditary syndrome neurofibro-
matosis 2. It encodes for merlin or schwannomin, proteins
involved in the organization of membrane extensions and
traffic and in cell growth, adhesion and signaling. Neurofi-
bromatosis 2-associated meningiomas and about 60% of
sporadic meningiomas are caused by mutation and/or dele-
tion of the NF2 gene.16,17 In our case, with the limitations of
the method of study (RT-PCR), we could not substantiate
a possible NF2 gene inactivation.
In summary, although infrequent, rhabdoid meningio-
mas can occur in children. Owing to its rarity, each new
case should be recorded to produce a better clinical, patho-
logical, molecular, prognostic and therapeutic characteriza-
tion of this lesion.
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